NIH Reporter #1R01AG088141-01A1

NIH Solicitation: Phase 1 Clinical Trial for NAD+ Augmentation in Down Syndrome and Alzheimer's Disease

This opportunity is a research grant solicitation from the National Institute on Aging (NIA), part of the NIH, for a phase 1 clinical trial on NAD+ augmentation in adults with Down syndrome and Alzheimer's disease. - Government Buyer: - National Institute on Aging (NIA), National Institutes of Health (NIH) - Based in Boston, Massachusetts - Products/Services Requested: - Research and development services for a phase 1 clinical trial - Focus on pharmacokinetics, safety, and efficacy of NAD+ augmentation - Target population: adults with Down syndrome and Alzheimer's disease - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Unique/Notable Requirements: - Clinical trial must address both prevention and reversal of Alzheimer's progression - Emphasis on NAD+ augmentation as the intervention - No set-aside or license restrictions - NAICS codes: 541712 (R&D in Physical, Engineering, and Life Sciences), 541714 (R&D in Biotechnology) - Estimated contract value: $801,359

Description

This is a research grant opportunity for a phase 1 clinical trial focusing on NAD+ augmentation in adults with Down syndrome to prevent or treat Alzheimer's disease. The project involves pharmacokinetics, safety, and efficacy assessments. The research aims to prevent or reverse the progression of Alzheimer's disease in this population. The deadline for responses is May 27, 2024.

View original listing